LATEST PRESS RELEASES

Red Light Holland Sells Approximately 350,000 Grams of Magic Truffles and Increases Points of Sale for iMicrodose Packs to Six More Smart Shops

Significant increase in number of points of sale for iMicrodose Packs now in 30 Smart Shops (including Brick and Mortar stores and online shops) plus (approximately) 350,000 grams of packaged magic truffles sold from the Red Light Holland Farm in Horst, the NetherlandsToronto, Ontario--(Newsfile Corp. - July 13, 2021) - Red Light Holland ... Read More...

Optimi Health Joins First Psychedelic Exchange Traded Fund

VANCOUVER, British Columbia, July 13, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products is pleased to announce its inclusion in the first psychedelics Exchange Traded Fund (“ETF”) (NEO: PSYK). The ETF began trading on the Neo Exchange as of J... Read More...

Lobe Sciences Appoints Gilberto Jesús Mendoza, President of the World Boxing Association, to Advisory Board

Vancouver, British Columbia--(Newsfile Corp. - July 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Gilberto Jesús Mendoza, President of the World Boxing Association, to its Advisory Board.Philip Young, CEO and Director of Lobe stated, "We are privileged to w... Read More...

Pure Extracts Submits Natural Health Product Licence Application for Blended Functional Mushroom Product

VANCOUVER, British Columbia, July 13, 2021 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly-owned subsidiary, Pu... Read More...

MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company’s First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound

The company's pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug, ibogaine. VANCOUVER, BC, July 13, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technolo... Read More...

MINDCURE Adopts Advance Notice Policy

VANCOUVER, BC, July 12, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that the Company's board of directors (the "Board") has adopted a policy that requires advance notice to the Company wit... Read More...

Field Trip Health Ltd. to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

TORONTO, July 08, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Ronan Levy, Co-Founder & Executive Chairman, will take part in a panel discussion and participate in one-on-one investor meetings at the Cowe... Read More...

Optimi Health Initiates Pathway to Nasdaq Listing

VANCOUVER, British Columbia, July 07, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products announced today that it has engaged the consulting services of Donohoe Advisory Associates LLC (“Donohoe Advisory”) to explore strategies to advance towar... Read More...

Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial

TORONTO, July 07, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce it has signed a partnership agreement with Clerkenwell Health (“Clerkenwell”). Clerkenwell is a leading psychedelic C... Read More...

Leading Psychedelic Wellness Company Delic Completes Acquisition of Ketamine Infusion Centers LLC, Adding Health Clinic Chain to Portfolio

Closing of Acquisition Expands Delic's Self-Sustaining Ecosystem with Existing Media/Education Platforms and Product Development Lab VANCOUVER, BC, July 6, 2021 - Delic Holdings, Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has completed its acquisition (the "Acquisition") of Ketami... Read More...

Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology

NCT's treatment of neurological disorders combined with Numinus' leadership in psychedelic-assisted therapy will offer opportunity to treat a range of chronic neurological conditions and common concurrent mental health challenges VANCOUVER, BC, July 6, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a mental health care company adv... Read More...

Maxim Group Initiates Coverage of Mind Cure Health

VANCOUVER, BC, June 30, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that Maxim Group analysts Jason McCarthy and Michael Okunewitch initiated coverage on MINDCURE. About Mind Cure Health I... Read More...

Allied Corp Signs Psilocybin Manufacturing Agreement To Produce Psilonex™ RX For What We Believe To Be The Largest Known Psilocybin Patient Cohort In The World

KELOWNA, British Columbia., June 29, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) an international medical company focused on creating and providing health solutions to address today’s medical mental health issues is pleased to announce the signing of a supply and manufacturing agreement with HAVN Life Sciences (CSE:HAVN... Read More...

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

TORONTO, June 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin, has achieved certain earn-out milestones for the period ... Read More...

PharmaTher To Participate in Grizzle Psychedelics Con

TORONTO, June 28, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Fabio Chianelli, Chief Executive Officer, will participate in the Grizzle Psychedelics Con today at 12 PM ET. “I am very excited to participate in this one-of-a-... Read More...

EGF Theramed Joint Venture Partner Pharmadelic Labs Announces Lab Services Agreement With Numinus Wellness

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - EGF Theramed Health Corp. (CSE: TMED) (OTC Pink: EVAHF) ("Theramed", the "Company") is pleased to announce that its subsidiary joint venture Pharmadelic Labs Inc. ("Pharmadelic") has signed a laboratory services agreement with Numinus Wellness Inc. (TSXV: NUMI) ("Numinus").Ph... Read More...

Numinus Announces Update to Escrow Release Schedule

VANCOUVER, BC, June 25, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that, in relation to its graduation from Tier 2 to Tier 1 of the TSX Venture Exchange (the "Exchange"), all securities o... Read More...

BetterLife Announces Exercise of Over-Allotment Option in Public Offering

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 25, 2021 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU ), is pleased to announce the partial exercise of the over-allotment option in conjunction with the Company’s $2,61... Read More...

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results

Field Trip completes FY2021 as the largest vertically integrated psychedelics company positioned to be a leader in the emerging industryContinues to leverage its early mover opportunity by investing in its drug development strategy and the build out of a globally recognized brand of psychedelic-assisted therapy centersClosed FY2021 with $... Read More...

Mydecine to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th

DENVER, June 23, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that Josh Bartch, CEO of Mydecine, will pa... Read More...

Red Light Holland to Partner with Leading Fresh and Dried Mushroom Producers on East Coast Facility

Red Light Holland to Acquire 51% of Acadian Exotic Mushrooms from Holburne Mushroom Farm and Carleton Mushroom Farms Owners Mike and Fernando MedeirosToronto, Ontario--(Newsfile Corp. - June 22, 2021) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged ... Read More...

Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2021 Financial Results Conference Call for Friday, June 25, 2021 At 8:00 am ET

TORONTO, June 17, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal fourth quarter and full year 2021 ended March 31, 2021, after market close on Thursday, June... Read More...